A Single Arm,Open Clinical Study of Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 16 Oct 2018 Status changed from not yet recruiting to recruiting.
- 07 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 25 Oct 2018.
- 06 Sep 2018 New trial record